CA2726472C — Solid pharmaceutical formulations comprising bibw 2992
Assigned to Boehringer Ingelheim International GmbH · Expires 2017-10-03 · 9y expired
What this patent protects
The present invention relates to a compacted powder consisting of 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo -2-buten-1-yl]amino} -7-((S)-tetrahydrofuran-3-yloxy)-quinazoline dimaleate (BIBW 2992 dimaleate) and optionally up to 1.0% of a lubricant, wherein…
USPTO Abstract
The present invention relates to a compacted powder consisting of 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo -2-buten-1-yl]amino} -7-((S)-tetrahydrofuran-3-yloxy)-quinazoline dimaleate (BIBW 2992 dimaleate) and optionally up to 1.0% of a lubricant, wherein: the powder is obtained by a roller compaction step and at least one sieving step after compaction, optionally in mixture with the lubricant in an amount of 0 to 1.0 % calculated on the amount of BIBW 2992 dimaleate by weight; and the powder has a particle size distribution of x10 < 200 µm, 1µm < x50 < 300 µm, 75 µm < x90 < 600 µm.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.